Ethmozine (moricizine HCl): a promising drug for "automatic" atrial ectopic tachycardia.

Abstract

Atrial ectopic tachycardia is an uncommon life-threatening supraventricular tachycardia in children and is resistant to usual antiarrhythmic drugs. Whereas the cellular mechanism of atrial ectopic tachycardia is unknown, atrial ectopic tachycardia may be due to a form of automaticity. Moricizine HCl has been used primarily for ventricular rhythm disturbances; the drug depresses abnormal automaticity and delayed after-depolarizations but has little effect on normal automaticity. Because of this property, we have used moricizine HCl in 4 patients with atrial ectopic tachycardia. As evidenced by continuous 24-hour Holter monitoring, moricizine HCl was successful in suppressing atrial ectopic tachycardia in each patient. During a limited follow-up (6 months) no side effects have occurred. Moricizine HCl is a promising primary drug for atrial ectopic tachycardia.

• Authors: V L Evans, A Garson Jr, R T Smith, J P Moak, P McVey, D G McNamara
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 60 Issue 11 Pg. 83F-86F (Oct 16 1987) ISSN: 0002-9149 [Print] United States
• PMID: 3310591 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-Arrhythmia Agents
• Phenothiazines
• Moricizine

Topics

• Adolescent
• Anti-Arrhythmia Agents (therapeutic use)
• Child, Preschool
• Electrocardiography
• Follow-Up Studies
• Humans
• Monitoring, Physiologic
• Moricizine
• Phenothiazines (therapeutic use)
• Tachycardia, Ectopic Atrial (drug therapy, physiopathology)
• Tachycardia, Supraventricular (drug therapy)